Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune is expected to have a strong, well-differentiated profile in the chronic urticaria market with the potential for oral convenience and a broad mechanism of action. Additionally, their entry into the migraine market with EVO301 adds a valuable, under-the-radar element to the company's story. Finally, Evommune has a credible potential for multi-asset franchise in the dermatology space, and their current progress and pipeline make them an attractive investment opportunity for potential buyers.

Bears say

Evommune is a clinical-stage biotechnology company with a focus on developing therapies for chronic inflammatory diseases such as chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). As a financial analyst, I have a negative outlook on the company's stock due to several fundamental reasons. These include the company's limited pipeline, high-risk clinical programs, possible delays in regulatory approval, competition from established biotech companies, and lack of revenue.

Evommune Inc (EVMN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 8 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.